Gleevec (Chronic Myeloid Leukemia)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 11
3.1.3 Clinical Staging 13
3.1.4 Prognosis 14
3.1.5 Quality of Life 15
3.2 Symptoms 16
4 Disease Management 17
4.1 Global Trends 17
4.1.1 Treatment Overview 17
4.1.2 Diagnostic Tests 20
4.1.3 Genetic Testing 21
4.1.4 Monitoring Patient Response to Treatment 23
4.1.5 Future Directions: Discontinuation Therapy 26
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
6 Product Profile – Gleevec (imatinib) 32
6.1 Overview 32
6.2 Efficacy 33
6.3 Safety 35
6.4 SWOT Analysis 36
6.5 Forecast 37
7 Appendix 38
7.1 Bibliography 38
7.2 Abbreviations 40
7.3 Methodology 42
7.4 Forecasting Methodology 42
7.4.1 Diagnosed CML patients 42
7.4.2 Drug-treated Patients on X Line of Therapy 43
7.4.3 General Pricing Assumptions 43
7.4.4 Compliance Assumptions for Oral TKIs 45
7.4.5 Individual Drug Assumptions 46
7.4.6 Generic Erosion 46
7.4.7 Pricing of New Market Entrants 46
7.5 Physicians and Specialists Included in this Study 47
7.6 Survey of High Prescribing Physicians 48
7.7 About the Authors 49
7.7.1 Authors 49
7.7.2 Epidemiologists 50
7.7.3 Global Director of Epidemiology and Clinical Trials Analysis 51
7.7.4 Global Head of Healthcare 52
7.8 About GlobalData 53
7.9 Contact Us 53
7.10 Disclaimer 53